Steven E. Nissen, M.D., chief cardiologist at the Cleveland
UNITED STATES - MARCH 26: Steven E. Nissen, M.D., chief cardiologist at the Cleveland Clinic, discusses his findings of a study of the drug Torcetrapib, during the American College of Cardiology Conference in New Orleans, Louisiana, Monday, March 26, 2007. The drug Pfizer Inc. stopped developing in December because of a link to excessive deaths failed to reduce artery-clogging plaque in studies presented today. Torcetrapib was supposed to work by raising levels of good cholesterol, or HDL, which scientists believe helps sweep bad cholesterol from arteries. Research presented at a scientific meeting used sophisticated imaging technology that peered inside patients' arteries to determine the drug has no effect on the build up of fatty plaque and raises blood pressure. (Photo by Scott Saltzman/Bloomberg via Getty Images)
EINE LIZENZ KAUFEN
Wie darf ich dieses Bild verwenden?
335,00 €
EUR
Getty ImagesSteven E. Nissen, M.D., chief cardiologist at the Cleveland, NachrichtenfotoSteven E. Nissen, M.D., chief cardiologist at the Cleveland Erstklassige Nachrichtenbilder in hoher Auflösung bei Getty ImagesProduct #:94579254
475€150€
Getty Images
In stockDETAILS
Einschränkungen:
Bei kommerzieller Verwendung sowie für verkaufsfördernde Zwecke kontaktieren Sie bitte Ihr lokales Büro.For editorial use only. Additional clearance required for commercial or promotional use, contact your local office for assistance. Any commercial or promotional use of Bloomberg content requires Bloombergs prior written consent.
Bildnachweis:
Redaktionell #:
94579254
Kollektion:
Bloomberg
Erstellt am:
26. März 2007
Hochgeladen am:
Lizenztyp:
Releaseangaben:
Kein Release verfügbar. Weitere Informationen
Quelle:
Bloomberg
Objektname:
pdir0807\PHi_j0208.JPG